Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia: letters to the editor - Jaramillo Segura, Sonia; Krisam, Johannes; Le Cornet, Lucian; Kratzmann, Markus; Baumann, Lukas; Eissymont, Olga; Crysandt, Martina; Görner, Martin; Kayser, Sabine; Krause, Stefan W.; Schliemann, Christoph; Gaska, Tobias; et al. (Haematologica, 2024)
Gesehen am 18.02.2025